A Phase 1b clinical trial of RSM 01 in infants
Latest Information Update: 29 Mar 2026
At a glance
- Drugs RSM 01 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
Most Recent Events
- 18 Mar 2026 According to SK bioscience media release, company announced that it has entered into a funding agreement with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) to receive financial support for early clinical development of its RSV (respiratory syncytial virus) preventive monoclonal antibody candidate, RSM01.Based on this support, SK bioscience plans to accelerate the Phase 1b clinical trial of RSM01 in infants.
- 16 Feb 2026 New trial record